CG肿瘤学的新治疗显示,难以治疗膀胱癌的成功率为74.5%,前景看好。 CG Oncology's new treatment shows promising 74.5% success rate in hard-to-treat bladder cancer.

CG肿瘤学报告说,其实验治疗 -- -- Cretostimogene -- -- 显示,在患高风险非肌肉入侵性膀胱癌的病人中,对卡介苗治疗没有反应的情况下,其完全反应率为74.5%。 CG Oncology reported that its experimental treatment, cretostimogene, showed a 74.5% complete response rate in patients with high-risk non-muscle invasive bladder cancer unresponsive to BCG treatment. 答复的平均持续时间超过27个月,没有严重副作用的报告。 The median duration of response exceeds 27 months, with no serious side effects reported. 该公司计划在2025年下半年申请FDA批准. The company plans to apply for FDA approval in the second half of 2025.